SCHEMBL24378718

SCHEMBL24378718

C[Si](C)(C)CCOC(=O)N1CCC(C(=O)O)CC1

nearest known ligand 0.51

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.51
NPC1 O15118 2/20 0.51
RAB9A P51151 2/20 0.51
GAA P10253 2/20 0.47
ALDH1A1 P00352 3/20 0.43
CHRM1 P11229 1/20 0.41
LMNA P02545 2/20 0.41
CYP2C19 P33261 1/20 0.40
HTT P42858 2/20 0.39
PKM P14618 1/20 0.39
POLB P06746 1/20 0.39
MAPT P10636 1/20 0.38
HSD17B10 Q99714 1/20 0.38
L3MBTL1 Q9Y468 3/20 0.38
THRB P10828 1/20 0.38
ATM Q13315 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22600784 0.86 GAA (0.46) SMN1; SMN2NPC1RAB9AGAAALDH1A1
SCHEMBL25795261 0.84 CHRNB2 (0.39) SMN1; SMN2NPC1RAB9AGAAALDH1A1
SCHEMBL6062450 0.84 GAA (0.42) SMN1; SMN2NPC1RAB9AGAAALDH1A1
SCHEMBL31171230 0.83 GAA (0.41) SMN1; SMN2GAAALDH1A1CHRM1LMNA
SCHEMBL31171227 0.83 GAA (0.41) SMN1; SMN2GAAALDH1A1CHRM1LMNA
SCHEMBL6063785 0.83 GAA (0.41) SMN1; SMN2GAAALDH1A1CHRM1LMNA
SCHEMBL3699376 0.83 GAA (0.45) SMN1; SMN2GAAALDH1A1CHRM1LMNA
SCHEMBL11578382 0.82 GAA (0.56) SMN1; SMN2NPC1RAB9AGAAALDH1A1
SCHEMBL21379226 0.82 GRIN2B (0.39) SMN1; SMN2GAAALDH1A1LMNAPOLB
SCHEMBL13113407 0.81 GAA (0.44) SMN1; SMN2GAAALDH1A1CHRM1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3967695-B1 1-(7-(QUINAZOLIN-4-YL)-2,7-DIAZASPIRO[3.5]NONAN-2-YL)PROP-2-EN-1-ONE DERIVATIVES AS KRAS INHIBITORS FOR THE TREATMENT OF CANCER BETTA PHARMACEUTICALS CO LTD (CN) 2024-01-17 EP disclosed
US-20230219956-A1 QUINAZOLINE COMPOUND AND PHARMACEUTICAL APPLICATION THEREOF BETTA PHARMACEUTICALS CO.,LTD (CN) 2023-07-13 US disclosed
US-20230219956-A1 QUINAZOLINE COMPOUND AND PHARMACEUTICAL APPLICATION THEREOF BETTA PHARMACEUTICALS CO.,LTD (CN) 2023-07-13 US disclosed
WO-2022083616-A1 QUINAZOLINE COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF 贝达药业股份有限公司 2022-04-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230219956-A1 QUINAZOLINE COMPOUND AND PHARMACEUTICAL APPLICATION THEREOF H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, ABCG2, NQO2 SMN1; SMN2 4670/4885NPC1 445/4885RAB9A 238/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.